Patent US1870930A successfully refreshed from Google Patents.
Patent US3801389A successfully refreshed from Google Patents.
Patent US4093608A successfully refreshed from Google Patents.
US4093608A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for purifying coagulation factor VIII using DEAE-crosslinked dextran
Assignee: Tanabe Pharma Corp
•
Filing: 1977-04-01
•
Granted: 1978-06-06
•
Expires: 1997-04-01
Abstract
Abstract A process for purifying coagulation factor VIII which comprises contacting a plasma or a plasma fraction containing prothrombin complex and coagulation factor VIII (antihemophilic factor A) with diethylaminoethyl-crosslinked dextran to adsorb and remove the prothrombin complex from said plasma or plasma fraction. Coagulation factor VIII thus obtained can be administered to control the bleeding in hemophilia A patients.
Inventors
- 👤 Yoshiro Iga
- 👤 Masashi Shiga
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:11
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83; Y10S530/831
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
72 words
A process for purifying coagulation factor VIII which comprises contacting for 10 to 60 minutes a human plasma or plasma fraction containing both prothrombin complex and factor VIII, said plasma or plasma fraction having an electroconductivity in the range of 7,000 to 12,000 μ /cm, a pH of 6.8 to 7.9, and a liquid temperature of 0° to 10° C, with diethylaminoethyl cross-linked dextran and thereby adsorbing and removing said prothrombin complex.
Claim 2
Dependent Claim
72 words
A process for purifying coagulation factor VIII which comprises contacting for 10 to 60 minutes a human plasma or plasma fraction containing both prothrombin complex and factor VIII, said plasma or plasma fraction having an electroconductivity in the range of 7,000 to 12,000 μ /cm, a pH of 6.8 to 7.9, and a liquid temperature of 0° to 10° C, with diethylaminoethyl cross-linked dextran and thereby adsorbing and removing said prothrombin complex.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-06-05 | 1981-12-05 | 1982-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-06-05 | 1985-12-05 | 1986-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-06-05 | 1989-12-05 | 1990-06-06 | $7700.00 | Window Closed / Lapsed |